Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mohammad Mobin, Moradi"'
Autor:
Majid Assadi, Reyhaneh Manafi-Farid, Esmail Jafari, Ahmad Keshavarz, GhasemAli Divband, Mohammad Mobin Moradi, Zohreh Adinehpour, Rezvan Samimi, Habibollah Dadgar, Narges Jokar, Benjamin Mayer, Vikas Prasad
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionThis study was conducted to evaluate the predictive values of volumetric parameters and radiomic features (RFs) extracted from pretreatment 68Ga-PSMA PET and baseline clinical parameters in response to 177Lu-PSMA therapy.Materials and met
Externí odkaz:
https://doaj.org/article/7c1656e928d54acbbaac06a8bc0c7ea0
Autor:
Reyhaneh Manafi-Farid, Bahar Ataeinia, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, Mohammad Mobin Moradi, Christian Pirich, Mohsen Beheshti
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target
Externí odkaz:
https://doaj.org/article/26bf6c0a5e174ea7829bf92113453a6e
Autor:
Mohammad Matin, Moradi, Mohammad Mobin, Moradi, Arash, Safaie, Alireza, Baratloo, Pooya, Payandemehr
Publikováno v:
The American Journal of Emergency Medicine. 54:165-171
Ketamine is known to be an effective factor in reducing pain without significant side effects.One of the limited side effects of Ketamine is agitation. Due to the reduction of this symptom with Haloperidol, we decided to design a randomized clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::552b6045c0392d1d2b7d7ff08bba5dd0
https://doi.org/10.1016/j.ajem.2022.02.012
https://doi.org/10.1016/j.ajem.2022.02.012
Autor:
Majid Assadi, Reyhaneh Manafi-Farid, Esmail Jafai, Ahmad Keshavarz, GhasemAli Divband, Mohammad Mobin Moradi, Zohreh Adinehpour, Rezvan Samimi, Habibollah Dadgar, Benjamin Mayer, Vikas Prasad
Publikováno v:
Journal of Clinical Oncology. 41:200-200
200 Background: 177Lu-PSMA therapy has been introduced as an effective therapeutic option for metastatic castration resistant prostate cancer (mCRPC). Since about one third of the treated patients show no biochemical response (BCR) after therapy, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9397de7c8a2322362c2f45a4f35bf06
https://doi.org/10.1200/jco.2023.41.6_suppl.200
https://doi.org/10.1200/jco.2023.41.6_suppl.200